Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.

Patient Relat Outcome Meas

Cardiovascular Research Centre, Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.

Published: July 2011

Platelets play a central role in atherothrombosis and subsequent development of acute coronary syndromes (ACS). The understanding of this process has driven a large body of evidence demonstrating the mortality and morbidity benefits of antiplatelet agents in the ACS population. As expected, however, these agents come with an intrinsically increased risk of bleeding which underlies the vast majority of their complications and adverse effects. In today's setting of compounding comorbidities and broadening indications, finding the balance between thrombosis prevention and bleeding risk remains the challenge for all clinicians considering these medications. This article reviews the current main antiplatelet agents that are available for clinical use and outlines their impact on ACS outcome. We also outline factors which affect the response to these agents and discuss strategies to optimize clinical outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417919PMC
http://dx.doi.org/10.2147/PROM.S9834DOI Listing

Publication Analysis

Top Keywords

acute coronary
8
coronary syndromes
8
antiplatelet agents
8
agents
5
antiplatelet therapy
4
therapy acute
4
syndromes current
4
current agents
4
agents impact
4
impact patient
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!